What role does the spirocyclic structure play in rolapitant patents?
Rolapitant is an NK1 (neurokinin-1) receptor antagonist. Patent filings for rolapitant (and its related chemical series) commonly describe the drug’s core heterocyclic framework and specify how particular ring systems—and, in some variants, spirocyclic motifs—are used to define structure–property relationships (potency, receptor selectivity, and physicochemical behavior). In patent language, the “spirocyclic” aspect typically matters because it changes three-dimensional shape, conformational rigidity, and often solubility/metabolism characteristics, which can translate into different binding and exposure profiles than more flexible analogs.
Which patents are most likely to mention “spirocyclic” rolapitant analogs?
Searchers typically find “spirocyclic” language in:
- Compound-claim patents covering rolapitant derivatives (substituted NK1 antagonists) where the inventors claim spirocyclic analogs within a broader genus.
- Intermediate/chemical-process patents where spirocyclic intermediates are produced (even if the final API is not itself spirocyclic in every example).
- Salt/polymorph or formulation patents only if the claimed examples include spirocyclic-related variants (less common than compound-claim filings).
To pinpoint the exact filings, you’d usually query patent databases for combinations of keywords such as “rolapitant,” “NK1,” “spiro,” and “spirocyclic,” plus the applicant/inventor names used in rolapitant prosecution.
How to search “rolapitant” + “spirocyclic” effectively (practical query strategy)
A high-recall patent search typically uses a mix of:
- The generic and chemical name: “rolapitant” plus known synonym spellings.
- Structural descriptors: “spiro,” “spirocyclic,” “spiro-fused,” and sometimes “spiro ring.”
- Target class: “NK1 receptor antagonist” or “neurokinin-1 antagonist.”
- Claim-anchoring terms: “compound of formula” / “wherein” language tied to the spirocyclic variable group.
If you have access to a structure search tool, you can also use the rolapitant scaffold and then filter results by substructure “spiro” features to isolate the most relevant family members.
What does “synthesis” mean for spirocyclic NK1 candidates in patents?
When patents mention spirocyclic synthesis for NK1 candidates, it usually includes at least one of these layers:
- A route to the spirocyclic ring system (forming the spiro junction).
- Functional-group installation steps (linkers, aryl substitutions, and heteroatom-bearing substituents).
- Final coupling to the NK1 pharmacophore portion (or deprotection/salt formation to reach the marketed form).
In many NK1 antagonist patent sets, the synthesis section is written so that the spirocyclic fragment can be swapped across examples, which is why “spirocyclic” appears frequently in the chemical definitions rather than just in preparation examples.
Are spirocyclic rolapitant analogs necessarily better than rolapitant?
Not automatically. Patent claim sets often include spirocyclic alternatives because they may improve one or more of the following, each of which can be experimentally validated:
- Binding potency or selectivity at NK1R.
- Metabolic stability and exposure.
- Crystallinity, polymorph control, or formulation performance.
- Safety margins tied to off-target effects (driven by structure).
However, a spirocyclic motif can also reduce solubility or create difficult solid-state behavior, so patents may claim them as part of a broader optimization program rather than as a universally superior replacement.
What about patent families, expiry, and freedom-to-operate risk?
Rolapitant belongs to a mature drug space, so “spirocyclic synthesis” patents might not be about the marketed rolapitant molecule itself. They can be:
- Improvement patents (new analogs, salts, polymorphs, or processes).
- Process patents that are harder to “design around” if they cover key intermediates.
- Genus patents that claim classes of spirocyclic derivatives, even if rolapitant is only one member of the family.
Because “spirocyclic” filings can cover related chemical space rather than the exact API, expiry and enforceability depend on the specific claim scope and jurisdiction. Without the exact patent documents you’re looking at (publication numbers or applicants), it’s not possible to map expiry or infringement risk precisely.
If you share one detail, I can synthesize the exact spirocyclic patent story
“Rolapitant patent synthesis spirocyclic” is broad. If you paste any of the following, I can produce a focused synthesis tied to specific documents:
- A patent publication number (e.g., “WO…”, “US…”, “EP…”).
- The applicant/assignee name.
- The compound name or intermediate name that is labeled spirocyclic in the document.
- A link or excerpt from the “compound of formula” section or the example synthesis scheme.
Sources
I don’t have any provided source documents or links in your message, so I cannot cite specific patent publications or claim language yet.